(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2017 (21.12.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/218981 A2

(51) International Patent Classification:
A61K 48/00 (2006.01) *C12N 15/861* (2006.01)

(21) International Application Number:
PCT/US2017/038012

(22) International Filing Date:
16 June 2017 (16.06.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/351,231 16 June 2016 (16.06.2016) US

(71) Applicant: **ADVERUM BIOTECHNOLOGIES, INC.** [US/US]; 1035 O'Brien Drive, Suite A, Menlo Park, CA 94025 (US).

(72) Inventors: **BLUMENKRANZ, Mark**; 1035 O'Brien Drive, Suite A, Menlo Park, CA 94025 (US). **GASMI, Mehdi**; 1035 O'Brien Drive, Suite A, Menlo Park, CA 94025 (US).

(74) Agent: **YIN, Eva F.** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304-1050 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2017/218981 A2

(54) Title: COMPOSITIONS AND METHODS FOR REDUCING OCULAR NEOVASCULARIZATION

FIG. 1



(57) Abstract: The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.

[Continued on next page]

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*